DCLK3 and migraine disorder: Since the first Food and Drug Administration (FDA) approval of G-protein-coupled receptor (GPCR)-directed antibody against RAMP1-CLR for the treatment of migraine in 2018 [21], the involvement of the RAMP1-CLR signaling axis in peripheral neurons has gained significant attention in recent years.